StreetInsider.com News Articles

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

Fri, 23 Oct 2026 19:20:00 -0400

FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartan

Findings provide further evidence of the biological effects of dual endothelin and angiotensin receptor antagonism and support FILSPARI as foundational treatment in IgAN

SAN DIEGO--(BUSINESS WIRE)--

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver,

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

Fri, 23 Oct 2026 19:20:00 -0400

FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartan

Findings provide further evidence of the biological effects of dual endothelin and angiotensin receptor antagonism and support FILSPARI as foundational treatment in IgAN

SAN DIEGO--(BUSINESS WIRE)--

Form 4 Travere Therapeutics, For: Oct 15 Filed by: Dube Eric M

Mon, 19 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261019/27203852.html

Form 144 Travere Therapeutics, Filed by: Dube Eric M

Thu, 15 Oct 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20261015/27193904.html

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 12 Oct 2026 17:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its common stock to 33 new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 142,580 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 12 Oct 2026 17:00:00 -0400

Travere to present Filspari kidney disease data at ASN 2026

Fri, 02 Oct 2026 10:00:40 -0400

Travere Therapeutics (Nasdaq: TVTX) plans to present nine data sets, including five oral presentations, on its drug Filspari (sparsentan) at the American Society of Nephrology Kidney Week 2026 in Denver, Colorado, October 21-25.

Final data from the Phase 2 SPARTAN study, an open-label trial evaluating once-daily oral Filspari as first-line therapy in IgA nephropathy (IgAN), showed 75% of the 12 participants achieved complete proteinuria remission at any point during the study. Kidney function remained stable through 110 weeks, with a chronic eGFR slope of −1.11 mL/min/1.73 m² per year from weeks 6 to 110.

A post hoc analysis from the Phase 3

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Fri, 02 Oct 2026 10:00:00 -0400

Two-year SPARTAN data show 75% complete proteinuria remission and eGFR stabilization with first-line use of FILSPARI in IgAN

FILSPARI demonstrated approximately 3x higher complete proteinuria remission rates and 75% lower kidney failure rates versus maximum labeled dose irbesartan in a post hoc analysis of FSGS patients without nephrotic syndrome from the DUPLEX Study

Featured ASN presentations reinforce FILSPARI’s growing role in transforming treatment and improving long-term outcomes in rare kidney disease

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Fri, 02 Oct 2026 10:00:00 -0400

Two-year SPARTAN data show 75% complete proteinuria remission and eGFR stabilization with first-line use of FILSPARI in IgAN

Featured ASN presentations reinforce FILSPARI’s growing role in transforming treatment and improving long-term outcomes in rare kidney disease

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American

Travere Therapeutics (TVTX) PT Raised to $89 at Guggenheim

Thu, 24 Sep 2026 06:11:54 -0400

(Updated - September 24, 2026 6:11 AM EDT)

Guggenheim analyst Vamil Divan raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $89.00 (from $75.00) while maintaining a Buy rating.

The analyst commented: "Travere announced this morning that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering certain methods of using Filspari (sparsentan) in focal segmental glomerulosclerosis (FSGS). Once issued, the patent is expected to provide US coverage for certain FSGS methods into October 2037, and the company plans to submit it for Orange Book listing promptly after it is granted. This is

Travere Therapeutics (TVTX) PT Raised to $89 at Guggenheim

Thu, 24 Sep 2026 06:11:54 -0400

(Updated - September 24, 2026 6:11 AM EDT)

Guggenheim analyst Vamil Divan raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $89.00 (from $75.00) while maintaining a Buy rating.

Travere gets patent allowance for Filspari use in kidney disease

Wed, 23 Sep 2026 07:00:30 -0400

Travere Therapeutics (Nasdaq: TVTX) announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application covering certain methods of using Filspari (sparsentan) in focal segmental glomerulosclerosis (FSGS), a rare kidney disease.

The application, U.S. Patent Application No. 19/253,120, is titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders." If issued, the patent is expected to provide U.S. coverage for certain methods of using sparsentan in FSGS through October 2037.

The patent will formally issue after payment of the issue fee and standard USPTO post-allowance processing. Travere said it plans to submit the

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental

Wed, 23 Sep 2026 07:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan in FSGS into October 2037.

The allowed application is expected to issue as a U.S. patent following payment of the issue fee and standard USPTO post-allowance

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental

Wed, 23 Sep 2026 07:00:00 -0400

The allowed application is expected to issue as a U.S. patent following payment of the issue fee and standard USPTO post-allowance

Form 8-K Travere Therapeutics, For: Sep 21

Mon, 21 Sep 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260921/27085457.html

Travere Therapeutics names new CEO effective December 2026

Mon, 21 Sep 2026 16:05:38 -0400

Travere Therapeutics (Nasdaq: TVTX) announced that Eric Dube, Ph.D., will step down as president and chief executive officer to focus on his health and family. Bradley L. Campbell has been appointed to succeed him, effective December 1, 2026.

Campbell previously served as president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc. He brings more than 25 years of biopharmaceutical experience, with nearly 20 years at Amicus in roles of increasing responsibility before becoming its CEO in 2022. He has also held commercial and business development roles at Genzyme and Bristol-Myers Squibb.

Dube, who became CEO in

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Mon, 21 Sep 2026 16:05:00 -0400

Eric Dube, Ph.D., has decided to step down as President and Chief Executive Officer in December Following Eight Years of Exemplary Leadership

Bradley L. Campbell to be Appointed President and CEO Effective December 1, 2026

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Mon, 21 Sep 2026 16:05:00 -0400

Eric Dube, Ph.D., has decided to step down as President and Chief Executive Officer in December Following Eight Years of Exemplary Leadership

Bradley L. Campbell to be Appointed President and CEO Effective December 1, 2026

Form 4 Travere Therapeutics, For: Sep 15 Filed by: ROTE WILLIAM E.

Thu, 17 Sep 2026 21:36:00 -0400

si-local-file:///var/storage/secattach/20260917/27077275.html

Form 4 Travere Therapeutics, For: Sep 15 Filed by: Heerma Peter

Thu, 17 Sep 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260917/27077271.html

Form 4 Travere Therapeutics, For: Sep 15 Filed by: Inrig Jula

Thu, 17 Sep 2026 21:34:00 -0400

si-local-file:///var/storage/secattach/20260917/27077263.html

Form 4 Travere Therapeutics, For: Sep 15 Filed by: REED ELIZABETH E

Thu, 17 Sep 2026 21:33:00 -0400

si-local-file:///var/storage/secattach/20260917/27077262.html

Form 4 Travere Therapeutics, For: Sep 15 Filed by: Dube Eric M

Thu, 17 Sep 2026 21:32:00 -0400

si-local-file:///var/storage/secattach/20260917/27077260.html

Form 4 Travere Therapeutics, For: Sep 15 Filed by: Cline Christopher R.

Thu, 17 Sep 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260917/27077259.html

Form 4 Travere Therapeutics, For: Sep 15 Filed by: Calvin Sandra

Thu, 17 Sep 2026 21:29:00 -0400

si-local-file:///var/storage/secattach/20260917/27077257.html